Rationale for Expanding the Use of Low-Dose Aspirin for Primary Cardiovascular Prevention during the COVID-19 Pandemic

Main Article Content

Arthur J. Siegel, M.D.

Abstract

The COVID-19 pandemic has decreased life-expectancy in the United States in 2021, causing over one million deaths especially in elderly persons with medical co-morbidities. While now waning, this epidemic continues to cause more than 500 fatalities per week mostly in individuals over70 years of age who are unvaccinated. Since viral epidemics have been shown to increase mortality due to atherosclerotic coronary heart disease and low-dose aspirin has been shown to reduce first myocardial infarctions by 44%, we recommend consideration of expanding the use of aspirin for primary cardiovascular prevention to reduce the cardiac morbidity and excess mortality associated with COVID-19 infections. Such aspirin use may be seen as especially appropriate for vulnerable elderly persons who qualify for treatment with Paxlovid (ritonavir-boosted nirmatrelvir) but are currently excluded for such in primary prevention guidelines of subspecialty societies. The rationale for this approach is further supported by recent proof of concept that vaccination, an alternative intervention for primary cardiovascular prevention, reduces the excess mortality associated with COVID-19 infection.


Can greater use of aspirin for primary cardiovascular prevention mitigate the excess cardiac mortality associated with COVID-19 as shown with prior viral epidemics 1-3? Recommendations from the 2019 ACC/AHA and 2021 ESC guidelines currently advise limited aspirin use for primary prevention except in persons aged 40 to 59 years with elevated ASCVD risk scores (10-year risk ≥10%) and for those aged 60 to 69 years only with risk ≥20% in the context of no excess risk of bleeding (Figure 1) 4,5. These guidelines have been endorsed by the United States Preventive Services Task Force, which acknowledge that low-dose aspirin in the primary prevention setting reduces the risk of major atherosclerotic cardiovascular events including myocardial infarction and ischemic stroke offset by an increased risk of gastrointestinal bleeding 7,8.  Currently endorsed guidelines specifically recommend against aspirin use in individuals at age 70 and beyond.

Article Details

How to Cite
SIEGEL, Arthur J.. Rationale for Expanding the Use of Low-Dose Aspirin for Primary Cardiovascular Prevention during the COVID-19 Pandemic. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3159>. Date accessed: 06 dec. 2022. doi: https://doi.org/10.18103/mra.v10i10.3159.
Section
Research Articles

References

1. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. Published online March 27, 2020. doi.10.1001/jamacardiol.2020.1017.
2. Madjid M, Safavi-Naemi P, Solomon SD, Vardery O. Potential effects of coronavirus on the cardiovascular system: A review JAMA Cardiol. published online March 27, 2020. doi.10.1001/jamacardiol.2020.1286.
3. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease deaths: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007; 28 (10).
4. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guidelines on the primary prevention of cardiovascular disease: J Am Coll Cardiol. 2019;74(10):ee177-e232.
5. Visseren FLJ, Mach F, Smulders YM, et al. ESC Scientific Document Group: 2021 Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.
6. United States Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: United States Preventive Services Task Force recommendation statement. JAMA. Published online April 26, 2022.doi:10.1001/jama.2022.4938
7. Mora S, Shufelt CL, Manson JE. Whom to treat for primary prevention of atherosclerotic cardiovascular disease: the aspirin dilemma. JAMA Intern Med. 2022:182(6):587-589.
8. Shufelt CL, Mora S, Manson JE. Aspirin for the primary prevention of atherosclerotic cardiovascular disease in women. JAMA, 2022 Published online, July 25, 2022 doi:10.1001/jama.2022.11951
9. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989; 321 (3): 129-135.
10. Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signaling pathway and incidence rates of atherosclerotic events and all-cause mortality: analysis from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018; 39: 3499–3507.
11. Siegel AJ. Aspirin use for enhanced primary cardiovascular prevention during the coronavirus-19 pandemic. J Cardiol Clin Practice.2020;3(2):1-2.
12. Siegel AJ. Aspirin use for primary cardiovascular prevention during the coronavirus-19 pandemic. Am J Med 2020; http://doi.org.10.1016.j.amjmed.2020.11.008
13. Siegel AJ. Pheidippides Redux: reducing the acute cardiac risk during marathon running. Am J Med. 2012; 125:630-635.
14. Siegel AJ. Pre-race aspirin to protect susceptible runners from cardiac arrest during marathons: is opportunity knocking? Open Heart. 2015. July 2; 2(1): e000102. Doi. 10.1136/openhrt-2014-000102.
15. Siegel AJ, Noakes TD. Can prerace aspirin prevent sudden cardiac death during marathons? Br J Sports Med. 2017;51(22): 1579-1582.
16. Siegel AJ, Noakes TD. Aspirin to prevent sudden cardiac death in athletes with high coronary artery calcium scores. Am J Med. 2019; 132:138-141.
17. Siegel AJ. Aspirin to reduce risk for sudden cardiac death in athletes with elevated C-reactive protein level. Am J Med. 2020. https://doi.org/10.1016/j.amjmed.2020.04.004
18. Chow JH, Kanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation and mortality in hospitalized COVID-19 patients. Anesthes Analges 2020.doi.10.1213.ANE.000000000005292.
19. Chow JH, Rahnavard A, Gomberg-Maitland M, et al. Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19. JAMA Network Open. 2022:5(3).e223890. doi.10.1001/jamanetworkopen.2022.3890,
20. Voruganti D, Bassareo PP, Calcaterra G, Mehta JL. Does aspirin save lives in patients with COVID-19? Heart.2021. http://dx.doi.org/10.1136/heartjnl-2021-320255.
21. Brett AS. Should patients take aspirin for primary cardiovascular prevention? Updated recommendations from the US Preventive Services Task Force. JAMA, 2022;327(16):1552-1554.
22. Magee LA, Nicolaidas KH, von Dadelszen P. Preeclampsia. N Engl J Med. 2022;386(19):1817-1832.
23. Faust SJ, Renton B, Junxiang C, et al. Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state. Lancet. 2022. Published August 22, 2022. DOI:https://doi.org/10.1016/S1473-3099(22)00547-3.
24. United States Department of Health and Human Services Paxlovid Information Sheet. https://www.mass.gov/info-details/free-telehealth-for-covid-19-treatment-with-paxlovid.
25. Havers SP, Pham H, Taylor CA, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states: January 2021 to April 2022. JAMA Int Med. Published online Sept 8, 2022.JAMAinternmed.doi:10.1001/jamainternmed.2022.4299.
26. Kim K, Hennekens CH, Martinez L et al. Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not age. Fam Med Com Health 2021; 9:e001475.doi.10.1136/fmed-2021-001475.
27. Fuster V, Gambus F, Patriciello A, et al. The polypill approach: an innovative strategy to improve cardiovascular health in Europe. BMC Pharmacol Toxicol. 2017; 18:10-18.